DEVELOPMENT AND CHARACTERIZATION OF IN SITU GEL OF XANTHAN GUM FOR OPHTHALMIC FORMULATION CONTAINING BRIMONIDINE TARTRATE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i7.25221Keywords:
Xanthan gum, Nil, Brimonidine tartrateAbstract
Objective: The goal of this study was to develop and characterize an ion-activated in situ gel-forming brimonidine tartrate, solution eye drops containing xanthan gum as a mucoadhesive polymer.
Method: Sol-gel formulation was prepared using gellan gum as an ion-activated gel-forming polymer, xanthan gum as mucoadhesive agent, and hydroxypropyl methyl cellulose (HPMC E50LV) as release retardant polymer. Phenylethyl alcohol is used as preservatives in borate buffer. The 23 factorial design was employed to optimize the formulation considering the concentration of gelrite, xanthan gum and HPMC as independent variables, gelation time, gel strength, and mucoadhesive force (N). Gelation time , gel strength, mucoadhesive force (N), viscosity (cP) and in vitro percentage drug release were chosen as dependent variables. The formulation was characteristics for pH, clarity, isotonicity, sterility, rheological behavior, and in vitro drug release, ocular irritation, and ocular visualization.
Result: Based on desirability index of responses, the formulation containing a concentration of gelrite (0.4%), xanthan gum (0.21%), and HPMC (HPMC E50 (0.24%) was found to be the optimized formulation concentration developed by 23 factorial design. The solution eye drops resulted in an in situ phase change to gel-state when mixed with simulated tear fluid. The gel formation was also confirmed by viscoelastic measurements. Drug release from the gel followed non-fickian mechanism with 88% of drug released in 10 h, thus increased the residence time of the drug.
Conclusion: An in situ gelling system is a valuable alternative to the conventional system with added benefits of sustained drug release which may ultimately result in improved patient compliance.
Downloads
References
Manish K, Kulkarni GT. Recent advances in ophthalmic drug delivery system. Int J Pharm Pharm Sci 2012;1:387-94.
Gupta S, Rajesh KS. Ophthalmic drug delivery systems with emphasis on in-situ hydrogels. Pharmagene 2013;1:80-7.
Ceulemans J, Vinckier I, Ludwig A. The use of xanthan gum in an ophthalmic liquid dosage form: Rheological characterization of the interaction with mucin. J Pharm Sci 2002;91:1117-27.
Bawa R, Hall RE, Kabra BP, Teague JE, Cagle GD, Markwardt KL, Shah MV. Gelling Ophthalmic Compositions Containing Xanthan Gum US.PATENT 6,261,547; 2001.
Deshmukh PK, Gattani SG. In vitro and in vivo consideration of novel environmentally responsive ophthalmic drug delivery system. Pharm Dev Technol 2013;18:950-6.
Chastaing G, Beaumont FR, Plazonnet B, Ferrand C, Rozier A. Ophthalmic Composition Containing a Carbonic Anhydrase Inhibitor and Xanthan Gum. US.PATENT 6,264,935; 2001.
Nayak SN, Sogali BS, Thakur RS. Formulation and evaluation of ph triggered in situ ophthalmic gel of moxifloxacin hydrochloride in-situ gelling system. Int J Pharm Pharm Sci 2012;4:452-9.
Dyer JR. Application of Absorption Spectroscopy of Organic Compounds. 8th ed. New Delhi: Prentice Hall Learning; 1991.
Kumar JR, Muralidharan S. Development of microparticle loaded gel (MPLGs) for prolong ocular drug delivery containing ketorolac tromethamine. J Pharm Sci Res 2014;6:148-52.
Kanoujia J, Sonker K, Pandey M, Koshy M, Shubhini AK, Saraf SA. Formulation and characterization of a novel pH-triggered in-situ gelling ocular system containing Gatifloxacin. Int Curr Pharm J 2012;1:43-9.
Dasankoppa FS, Solankiy P, Sholapur HN, Jamakandi VG, Sajjanar VM, Walveka PM. Formulation and evaluation of a novel in situ gum base ophthalmic drug delivery system of linezolid. Sci Pharm 2008;76:515- 32.
Farheen T, Sadhana RS, Shaikh AM, Zudbuke N, Ali SA. Formulation development and evaluation of in-situ ophthalmic gel of sodium cromoglycate. Der Pharm Sin 2013;4:109-18.
Franklin KR, Kowalski AJ, Marie Esser ICH, Rowe KE. Antiperspirant Compositions US.PATENT 2000061082; 2000.
Dave V, Paliwal S, Yadav S, Sharma S. Effect of in vitro transcorneal approach of aceclofenac eye drops through excised goat, sheep, and buffalo corneas. Sci World J 2015;2015:1-7.
Kumar K, Mishra IN, Sandhya J. Study of storage periods of culture suspension of Escherichia coli. Int J Pharma Sci Drug Res 2013;5:36-7.
Smith R, von Tress M, Tubb C, Vanhaecke E. Evaluation of the scanRDI_ as a rapid alternative to the pharmacopoeial sterility test method: Comparison of the limits of detection. J Pharm Sci Tech 2010;64:356-63.
Sterility Testing: Pharmaceutical Products. Available from: http://www. newagepublishers.com/sample chapter.pdf. [Last cited 2016 Feb].
General Requirements For The Sterility Of Biological Substance. Available from: http://www.who.int/biologicals/publications/sterility/ WHO_TRS_530_A4.pdf. [Last cited 2016 Feb].
Pharmaceutical Microbiology and Biotechnology. Available from: http://www.nsdl.niscair.res.in/sterilization methods and Principles.pdf. [Last cited 2016 Feb].
Current Status of In Vitro Test Methods for Identifying Ocular Corrosives and Severe Irritants: Hen’s Egg Test-Chorioallantoic Membrane Test Method. Available from: http://www.iccvam.niehs.nih. gov/methods/ocudocs/ocu_brd.htm#hetcam. [Last cited 2015 Aug]
Day 9 Of Incubation: The Story Inside The Chicken Egg. Available from: http://www.raising-happy-chickens.com/incubation-day-9.html. [Last cited 2015 Aug].
Guss R, Johnson R, Maurice D. Rhodamine B as a test molecule in intraocular dynamics. Invest Ophthalmol Vis Sci 1984;25:758-62
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
